Supplementary Figure 5 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer

This is a Experimental Study study.

Key Points

PI3K-mTOR inhibition effectively targets the p85β:H3K27Me3 switch, enhancing cancer treatment.
The study demonstrates significant potential in overcoming metastasis and immunotherapy resistance in triple-negative breast cancer.
Evidence shows that targeting EZH2 through PI3K–mTOR pathways can alter cancer progression.
The findings highlight a critical link between metabolic pathways and cancer resilience mechanisms.

We only have this paper's title and publication details.

PI3K-mTOR inhibition reduces immunotherapy resistance in triple-negative breast cancer, suggesting new treatment avenues.

Supplementary Figure 5. PI3K-mTOR inhibition targets the p85β:H3K27Me3 switch.

No takes yet. Share an insight, caveat, or question.

Melino et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share